Here's Why Intercept Pharmaceuticals Stock Rose 48.9% in November
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT), a biopharmaceutical company, were up 48.9% in November, according to data from S&P Global Market Intelligence. An interim analysis of the company's big non-alcoholic steatohepatitis (NASH) trial provided the lift last month.
Since 2015, Intercept has been running a trial with its only commercial-stage drug, Ocaliva, and NASH patients with fibrosis. There still aren't any drugs available to halt the progression of NASH, but the Food and Drug Administration has clearly stated that it's willing to approve one that can reduce fibrosis or resolve the inflammation that damages the liver.
Image source: Getty Images.
Source Fool.com
